Company: LENZ
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001815776-25-000019
Chunk: 335

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 8
Chunk 335
---
 and equipment(468)(30)Net cash used in investing activities(154,479)(29,621)Cash flows from financing activitiesProceeds from issuance of Series B convertible preferred stock, net of issuance costs— 82,976 Deferred offering costs— (2,479)Proceeds from issuance of common stock, net of issuance costs79,513 — Cash, cash equivalents, and restricted cash acquired in connection with the Merger117,824 — Merger transaction costs(2,373)— Proceeds from exercises of stock options4,038 203 Net cash provided by financing activities199,002 80,700 Net decrease in cash, cash equivalents, and restricted cash(14,868)(9,301)Cash and cash equivalents, beginning of the period35,140 44,441 Cash, cash equivalents, and restricted cash, end of the period$20,272 $35,140 Supplemental cash flow informationConversion of Series A, A-1, and B convertible preferred stock to common stock$137,490 $— Conversion of Class B convertible common stock to common stock$5,900 $— Reclassification of warrant liability to equity$1,918 $— Prepaid expenses and other current assets assumed in the Merger$1,313 $— Accounts payable and accrued liabilities assumed in the Merger$2,950 $— Right-of-use assets assumed in the Merger in exchange for operating lease liabilities$74 $— Right-of-use assets obtained in exchange for operating lease liabilities$1,116 $190 Property and equipment included in accounts payable and accrued expenses$203 $— Deferred offering costs included in accounts payable and accrued expenses$— $260 

See accompanying notes to consolidated financial statements. 

105